SIGA Faces Q2 Earnings with Clouded Revenue Visibility After EU MPOX Approval Loss

What happened

SIGA Technologies heads into its Q2 2026 earnings report with shares down roughly 40% since April, reflecting mounting concerns over its single-product reliance on TPOXX. First-quarter results were weak, with stagnant revenues and widening losses, as the company leaned on a $26 million BARDA delivery and a $13 million Asia Pacific contract to sustain the top line. The loss of EU approval for TPOXX in mpox removes a key international growth lever and casts doubt on the drug’s broader clinical utility. Management is advancing pediatric and post-exposure prophylaxis versions, but these programs will not generate material near-term revenue. Consequently, the upcoming report will be closely watched for any indication of renewed BARDA procurement or a plan to offset the shrinking commercial opportunity.

Implication

The loss of EU mpox approval closes a commercial avenue and may signal broader regulatory skepticism that could spread to other jurisdictions. BARDA has largely exercised the 19C contract, and without a successor, revenue will be limited to dwindling international orders and R&D reimbursements. The Q1 2026 reliance on a one-time BARDA delivery and a single Asia Pacific deal underscores the fragility of the top line. While pediatric and PEP labels could expand TPOXX’s addressable market, these are years away and contested by competitors like Tembexa. Investors should brace for Q2 results that may confirm a structural decline unless new orders materialize.

Thesis delta

The investment case has deteriorated significantly since the prior assessment. Loss of EU mpox approval and the ongoing absence of fresh BARDA commitments materially reduce the probability of sustained cash flows, elevating the risk that SIGA’s apparent deep value is a classic value trap. We now view the stock as a HOLD at best, with a clear SELL bias unless Q2 results reveal a concrete path to revenue replacement.